Periods, Pregnancy and AI: Why Investors Are Flocking to India's $35 Billion Femtech Opportunity

The ₹99 Gynaecologist Appointment

On a crowded Mumbai local train, a 28-year-old marketing executive discreetly opens her phone. She types a question she has been hesitant to ask even her closest friends. Within seconds, an AI chatbot responds. A few taps later, she books a video consultation with a gynaecologist for ₹99. No waiting rooms. No judgmental stares. No time off work.

This is Pinky Promise — India's first AI-led digital clinic for women. In January 2026, the Mumbai-based startup raised $1 million in pre-seed funding led by Rebalance Angel Community, with participation from angels including former TCS MD and CEO N. Chandrasekaran. The app offers 24/7 chat-first gynaecological care in Hinglish and English, with consultations starting at just ₹99. The fresh capital will fund the expansion of integrated care services, the rollout of physical clinics, and the growth of its nutritional supplements range.

Pinky Promise is not an outlier. It is the leading edge of a tidal wave. India's femtech market is projected to grow from $1.49 billion in 2025 to $5.52 billion by 2034, registering a CAGR of 15.7%. Other estimates place the market at $1.23 billion in 2023, expected to reach $3.88 billion by 2030 at a CAGR of 17.8%. And the convergence of three forces — rising female disposable income, digital health adoption post-pandemic, and a cultural shift away from taboo — is accelerating the sector like never before.

The Market: A $5.5 Billion Opportunity by 2034

To understand the scale of India's femtech opportunity, one must look at the broader beauty and personal care canvas. The India beauty and personal care market was valued at approximately $34.9 billion in 2022 and is projected to reach $49.1 billion by 2032. The cosmetics market alone, valued at $23.9 billion in 2024, is expected to grow to $44.6 billion by 2032 at a CAGR of 8.3%. The skincare segment, in particular, is growing at a staggering 14.6% CAGR, expected to soar from $2.9 billion in 2023 to $12.9 billion by 2034.

What does beauty and personal care have to do with femtech? Everything. The same women buying premium skincare are also seeking better menstrual hygiene products, fertility tracking solutions, menopause support, and digital gynaecology services. The channels are identical — D2C websites, quick commerce platforms like Blinkit and Zepto, and premium retail stores. The investor thesis is identical — high repeat rates, strong brand loyalty, and a massive underpenetrated market.

The D2C Femtech Pioneers

Nua: The Deepika Padukone‑Backed Category Creator

Perhaps the most visible femtech brand in India is Nua, a women's wellness and hygiene platform that started with organic sanitary pads and has since expanded into intimate care, skincare, and overall wellness.

In March 2026, Nua raised a pre-Series C round led by Mirabilis Investment Trust, the family office of Infosys co-founder K. Dinesh. The round, valued at approximately ₹35 crore, saw participation from existing investors including Lightbox VC, Kae Capital, actress Deepika Padukone, and former Unilever global president Vindi Banga. Nua has now raised over $22 million in total venture funding.

What makes Nua distinctive is its community‑first approach. The brand has a community of over 5.5 lakh women and offers a subscription model that delivers customised sanitary pad boxes based on individual flow and skin sensitivity. Deepika Padukone, who is also the face of the brand, reportedly invested $7.1 million in an earlier Series A round.

HealthFab: From Period Underwear to Full‑Stack Period Care

In May 2026, Bengaluru‑based HealthFab raised ₹20 crore in a Series A round led by Atomic Capital. The funding will fuel the startup's expansion beyond period underwear into a comprehensive period care platform encompassing pain, sleep and energy solutions.

HealthFab has already built a base of 5 lakh women users, reporting 3x year-on-year revenue growth with strong repeat purchases. The company has raised nearly $3.7 million in total funding to date, including $1 million in its pre-Series A round in 2025 from investors including Mistry Ventures, BeyondSeed, and angel investors Anupam Mittal, Aman Gupta, Vineeta Singh and Peyush Bansal.

Pinky Promise: The AI‑Led Digital Clinic

Pinky Promise's $1 million pre-seed raise is small in absolute terms but significant in what it represents: the convergence of AI and women's healthcare. The platform offers AI-assisted consultations with gynaecologists, with prices starting at ₹99. Available 24/7 in Hinglish and English, the app is designed to reach women in Tier 2 and 3 cities who may not have easy access to quality gynaecological care.

The investment will fund the expansion of integrated care services, the rollout of physical clinics, and the growth of its nutritional supplements range. If successful, Pinky Promise could become the "culturally fluent tele‑gynaecology" platform that India has long needed.

Newmi Care: The Full‑Stack Outpatient Platform

In May 2026, Newmi Care raised $1.5 million in a seed funding round led by Sprout Venture Partners, with participation from D2C Insider Angels and investor Abhishek Goyal (Tracxn).

Newmi Care is a full‑stack outpatient platform focused on women's health across all life stages — from puberty to menopause, including PCOS, fertility, pregnancy, postpartum and cancers. With the fresh funds, the startup plans to establish women's clinics in northern and western India, advance its technology, drive product innovation and expand its team.

Plush: The Feminine Hygiene Scale‑Up

Chennai‑based Plush is a feminine hygiene D2C brand that has raised $8.13 million to date, including a ₹40 crore Series B round led by Premji Invest's former senior partner Rahul Garg. The company is targeting ₹200 crore ARR and currently operates at a ₹100 crore ARR with EBITDA‑level profitability. Post‑funding, Plush's valuation is estimated at approximately ₹281 crore (about $33 million), representing a three‑fold increase from its previous pre‑Series B round.

The Investment Thesis: Why VCs Are Betting Big

Why is femtech suddenly on every investor's radar? Three structural reasons.

First, underpenetration. Despite India having one of the largest populations of women in the world, the femtech sector remains nascent. Menstrual hygiene product penetration is still under 50% in rural areas, digital gynaecology services are virtually non‑existent outside metros, and menopause support is almost entirely absent from the healthcare conversation. The runway is enormous.

Second, high repeat rates. Femtech products — sanitary pads, supplements, skincare — are high‑frequency, high‑loyalty categories. A customer who finds a brand she trusts is likely to stay for years. This is the dream economics of D2C.

Third, cultural tailwinds. The taboo around menstruation, menopause and reproductive health is finally being broken — by social media, by celebrity endorsements (Deepika Padukone for Nua), and by a generation of young women who refuse to accept silence as the default.

The Global Indian Takeaway

For the diaspora, India's femtech surge offers three clear opportunities.

First, invest in the pipeline. Nua's pre‑Series C, Pinky Promise's pre‑seed, HealthFab's Series A — these are all accessible to accredited investors through syndicates and angel networks. The valuations are still reasonable, and the upside is significant.

Second, build cross‑border distribution bridges. Indian femtech brands are hungry for US and European distribution, particularly in the large Indian diaspora markets of the US, UK, Canada and Australia. Diaspora professionals with retail, wholesale or e‑commerce networks can serve as exclusive distributors or marketplace partners.

Third, mentor and advise. Femtech founders — many of them women — desperately need experienced operators who have scaled D2C or healthcare brands globally. A diaspora mentor can add immense value, and potentially earn equity or advisory fees.

The Final Word

The ₹99 Pinky Promise consultation. The ₹20 crore HealthFab raise. The Deepika Padukone‑backed Nua. The $1.5 million Newmi Care seed round. The ₹40 crore Plush Series B. These are not isolated data points. They are proof that India's femtech sector has finally arrived.

For generations, women's health in India was shrouded in silence, stigma and neglect. The D2C femtech revolution is dismantling that silence — one chatbot, one sanitary pad subscription, one clinic at a time. And the numbers suggest that investors, founders and consumers are all paying attention.

The future of femtech is not just female‑focused. It is female‑led, female‑funded and female‑designed. And it is being built, right now, in India.

CHART: "India's Femtech & Women's Health D2C – At a Glance (2026)"

Other Key Metrics: